zolpidem has been researched along with Aging in 20 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report a case of an elderly woman sustaining an episode of delirium after one dose of zolpidem." | 7.71 | Delirium associated with zolpidem. ( Brodeur, MR; Stirling, AL, 2001) |
| "Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1." | 5.31 | Zolpidem use and hip fractures in older people. ( Avorn, J; Bohn, RL; Glynn, RJ; Mogun, H; Wang, PS, 2001) |
| "The SNR effects on seizures are site-specific within the SNR and developmentally regulated." | 5.30 | Regional and age specific effects of zolpidem microinfusions in the substantia nigra on seizures. ( Löscher, W; Moshé, SL; Velísková, J, 1998) |
| " Differences in the effects produced by eszopiclone and zolpidem as a function of the aging process likely reflect the fact that they bind to different subunits of the GABA(A) receptors, which are differentially reactive to the aging process." | 3.75 | The impact of age on the hypnotic effects of eszopiclone and zolpidem in the guinea pig. ( Chase, MH; Xi, M, 2009) |
| "To report a case of an elderly woman sustaining an episode of delirium after one dose of zolpidem." | 3.71 | Delirium associated with zolpidem. ( Brodeur, MR; Stirling, AL, 2001) |
| "This study analyzed pharmacokinetic parameters of zolpidem, formulated as a sublingual zolpidem tartrate tablet (ZST; Intermezzo®), in healthy elderly males and females (mean age 72 years) and in non-elderly males and females (34 years)." | 2.79 | Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects. ( Greenblatt, DJ; Harmatz, JS; Harris, SC; Kapil, RP; Roth, T; Singh, NN; Steinberg, F, 2014) |
| "01), Cmax was increased (93 vs 40 ng ml-1, P < 0." | 2.71 | Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ( Greenblatt, DJ; Harmatz, JS; Hesse, LM; Ochs, HR; Olubodun, JO; Roubenoff, R; Shader, RI; von Moltke, LL, 2003) |
| "The prevalence of insomnia increases with age and affects up to 35% of community-dwelling adults with dementia." | 2.45 | Non-pharmacologic treatment of insomnia in persons with dementia. ( Darvishi, R; Kunik, ME; Shub, D, 2009) |
| "This article will review the causes of insomnia in the elderly, the approach to patient evaluation, and the nonpharmacologic and pharmacologic treatment of insomnia." | 2.43 | Insomnia in the elderly: cause, approach, and treatment. ( Gammack, JK; Kamel, NS, 2006) |
| "The prevalence of adverse reactions to zolpidem was investigated in a subpopulation of participants in the Drug Event Monitoring project of the Japan Pharmaceutical Association." | 1.43 | Safety analysis of zolpidem in elderly subjects 80 years of age or older: adverse event monitoring in Japanese subjects. ( Hirota, S; Ishizuka, T; Kajiwara, A; Koda, H; Morita, K; Murase, M; Nakagawa, K; Oniki, K; Saruwatari, J; Yamamura, M, 2016) |
| "Zolpidem is a widely used hypnotic drug acting via benzodiazepine binding sites on GABA(A) receptors." | 1.36 | Zolpidem is a potent anticonvulsant in adult and aged mice. ( Pericić, D; Vlainić, J, 2010) |
| " In contrast, chronic administration of zolpidem produced little or no effect on proliferation in either age group, despite marked differences in basal proliferation levels between the two age groups." | 1.35 | Effects of the hypnotic drug zolpidem on cell proliferation and survival in the dentate gyrus of young and old rats. ( Fornal, CA; Jacobs, BL; Takase, LF, 2009) |
| "The zolpidem-induced increase of decay times, amplitude and charge transfer and alpha1-ir expression were the lowest in PN5-9 males but increased with age, in both genders." | 1.35 | Age- and gender-related differences in GABAA receptor-mediated postsynaptic currents in GABAergic neurons of the substantia nigra reticulata in the rat. ( Chudomel, O; Galanopoulou, AS; Herman, H; Moshé, SL; Nair, K, 2009) |
| "Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1." | 1.31 | Zolpidem use and hip fractures in older people. ( Avorn, J; Bohn, RL; Glynn, RJ; Mogun, H; Wang, PS, 2001) |
| "The SNR effects on seizures are site-specific within the SNR and developmentally regulated." | 1.30 | Regional and age specific effects of zolpidem microinfusions in the substantia nigra on seizures. ( Löscher, W; Moshé, SL; Velísková, J, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Treves, N | 1 |
| Perlman, A | 1 |
| Kolenberg Geron, L | 1 |
| Asaly, A | 1 |
| Matok, I | 1 |
| Greenblatt, DJ | 2 |
| Harmatz, JS | 2 |
| Singh, NN | 1 |
| Steinberg, F | 1 |
| Roth, T | 1 |
| Harris, SC | 1 |
| Kapil, RP | 1 |
| Kajiwara, A | 1 |
| Yamamura, M | 1 |
| Murase, M | 1 |
| Koda, H | 1 |
| Hirota, S | 1 |
| Ishizuka, T | 1 |
| Morita, K | 1 |
| Oniki, K | 1 |
| Saruwatari, J | 1 |
| Nakagawa, K | 1 |
| Takase, LF | 1 |
| Fornal, CA | 1 |
| Jacobs, BL | 1 |
| Shub, D | 1 |
| Darvishi, R | 1 |
| Kunik, ME | 1 |
| Xi, M | 1 |
| Chase, MH | 1 |
| Chudomel, O | 1 |
| Herman, H | 1 |
| Nair, K | 1 |
| Moshé, SL | 2 |
| Galanopoulou, AS | 1 |
| Vlainić, J | 1 |
| Pericić, D | 1 |
| Bocca, ML | 1 |
| Marie, S | 1 |
| Lelong-Boulouard, V | 1 |
| Bertran, F | 1 |
| Couque, C | 1 |
| Desfemmes, T | 1 |
| Berthelon, C | 1 |
| Amato, JN | 1 |
| Moessinger, M | 1 |
| Paillet-Loilier, M | 1 |
| Coquerel, A | 1 |
| Denise, P | 1 |
| Olubodun, JO | 1 |
| Ochs, HR | 1 |
| von Moltke, LL | 1 |
| Roubenoff, R | 1 |
| Hesse, LM | 1 |
| Shader, RI | 1 |
| Kamel, NS | 1 |
| Gammack, JK | 1 |
| Ruano, D | 2 |
| Benavides, J | 1 |
| Machado, A | 2 |
| Vitorica, J | 2 |
| Rovira, C | 1 |
| Ben-Ari, Y | 1 |
| Velísková, J | 1 |
| Löscher, W | 1 |
| Roberts, AA | 1 |
| Kellogg, CK | 1 |
| Taketo, M | 1 |
| Yoshioka, T | 1 |
| Brodeur, MR | 1 |
| Stirling, AL | 1 |
| Wang, PS | 1 |
| Bohn, RL | 1 |
| Glynn, RJ | 1 |
| Mogun, H | 1 |
| Avorn, J | 1 |
| Bacon, E | 1 |
| de Barry, J | 1 |
| Gombos, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Benefits of Individualized Advice Administration on Quality of Sleep for the Elderly Living at Home Prospective, Monocentric and Open Study[NCT03594851] | 45 participants (Actual) | Interventional | 2018-01-08 | Completed | |||
| SPIDER: A Structured Process Informed by Data, Evidence and Research - A Research and Quality Improvement Collaboration Supporting Practices in Improving Care for Complex Elderly Patients[NCT03689049] | 104 participants (Anticipated) | Interventional | 2018-03-26 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for zolpidem and Aging
| Article | Year |
|---|---|
Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis.
Topics: Accidental Falls; Acetamides; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Azabicyclo Compoun | 2018 |
Non-pharmacologic treatment of insomnia in persons with dementia.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antidepressive Agents, Tricyclic; Circadian Rhyth | 2009 |
Insomnia in the elderly: cause, approach, and treatment.
Topics: Acetamides; Aged; Aging; Antidepressive Agents; Azabicyclo Compounds; Behavior Therapy; Benzodiazepi | 2006 |
3 trials available for zolpidem and Aging
| Article | Year |
|---|---|
Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects.
Topics: Administration, Sublingual; Adult; Aged; Aging; Area Under Curve; Cross-Over Studies; Female; Health | 2014 |
Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects.
Topics: Aged; Aging; Analysis of Variance; Automobile Driving; Azabicyclo Compounds; Circadian Rhythm; Cross | 2011 |
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aging; Chromatography, High Pressure Liquid; D | 2003 |
14 other studies available for zolpidem and Aging
| Article | Year |
|---|---|
Safety analysis of zolpidem in elderly subjects 80 years of age or older: adverse event monitoring in Japanese subjects.
Topics: Aged, 80 and over; Aging; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; | 2016 |
Effects of the hypnotic drug zolpidem on cell proliferation and survival in the dentate gyrus of young and old rats.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Bromodeoxyuridine; Cell Proliferation; Cell Survi | 2009 |
The impact of age on the hypnotic effects of eszopiclone and zolpidem in the guinea pig.
Topics: Age Factors; Aging; Analysis of Variance; Animals; Azabicyclo Compounds; Dose-Response Relationship, | 2009 |
Age- and gender-related differences in GABAA receptor-mediated postsynaptic currents in GABAergic neurons of the substantia nigra reticulata in the rat.
Topics: Aging; Animals; Cell Differentiation; Female; GABA Agonists; GABA-A Receptor Agonists; gamma-Aminobu | 2009 |
Zolpidem is a potent anticonvulsant in adult and aged mice.
Topics: Age Factors; Aging; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interact | 2010 |
Aging-associated changes in the pharmacological properties of the benzodiazepine (omega) receptor isotypes in the rat hippocampus.
Topics: Aging; Animals; Binding Sites; gamma-Aminobutyric Acid; Hippocampus; Isomerism; Male; Membranes; Pyr | 1995 |
Developmental study of benzodiazepine effects on monosynaptic GABAA-mediated IPSPs of rat hippocampal neurons.
Topics: Aging; Animals; Anti-Anxiety Agents; Carbolines; Convulsants; Culture Techniques; Dose-Response Rela | 1993 |
Absence of modifications of the pharmacological properties of the GABAA receptor complex during aging, as assessed in 3- and 24-month-old rat cerebral cortex.
Topics: Affinity Labels; Aging; Animals; Anti-Anxiety Agents; Binding, Competitive; Cerebral Cortex; Flunitr | 1993 |
Regional and age specific effects of zolpidem microinfusions in the substantia nigra on seizures.
Topics: Aging; Animals; Anticonvulsants; Convulsants; Flurothyl; Hypnotics and Sedatives; Male; Microinjecti | 1998 |
Synchronous postnatal increase in alpha1 and gamma2L GABA(A) receptor mRNAs and high affinity zolpidem binding across three regions of rat brain.
Topics: Aging; Analysis of Variance; Animals; Binding Sites; Binding, Competitive; Brain; Cerebellum; Cerebr | 2000 |
Developmental change of GABA(A) receptor-mediated current in rat hippocampus.
Topics: Aging; Animals; Animals, Newborn; Diazepam; Electric Conductivity; Electric Stimulation; GABA Antago | 2000 |
Delirium associated with zolpidem.
Topics: Adult; Aged; Aged, 80 and over; Aging; Area Under Curve; Delirium; Dose-Response Relationship, Drug; | 2001 |
Zolpidem use and hip fractures in older people.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Benzot | 2001 |
Differential ontogenesis of type I and II benzodiazepine receptors in mouse cerebellum.
Topics: Aging; Animals; Cerebellum; Flunitrazepam; Mice; Models, Biological; Pyridazines; Pyridines; Recepto | 1991 |